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ABSTRACT 
Aim 
The aim of this study was to provide additional information into the adherence 
patterns of Australians on anti-retroviral therapy (ART), using prescription refill 
records as the measure of adherence. The study also tried to prove the existence of an 
association between forgiveness of current antiretroviral agents and viral suppression 
in patients with HIV 
Methods 
Using data collected from an earlier study, statistical analyses was carried out using 
SPSS software to determine the relationship between various study variables and 
adherence using two cut off points of <88% and   88% 
Results 
Several factors were found to be predictive of adherence in the study population. 
These included duration on antiretroviral therapy, and number of pills taken daily for 
co-morbidities and total daily pill burden. A statistically significant association was 
also seen between viral suppression and adherence rates using the study cut offs 
(p=0.02). Patients with adherence rates of at least 88% were more likely to have 
undetectable viral loads, when compared to patients with lower adherence rates. This 
was believed to be due to the forgiveness of currently used ART regimens. 
Conclusion 
Forgiveness of current antiretroviral agents e.g boosted protease inhibitors and 
efavirenz allows viral suppression to be seen at levels of adherence lower than 
recommended levels. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 iv 
ACKNOWLEDGEMENTS 
I’d like to acknowledge the efforts of my supervisors Ms. Judith Burrows and Fiona 
Clark for all their hard work and support towards ensuring this work was completed 
in a timely manner. 
I’d also like to thank both Ausaid (Australian agency for international development) 
and the Nigerian government. Without which this whole degree would not have been 
possible. 
Finally I’d like to thank my family and friends, especially my husband for all their 
support. Having you all behind me made this all a little easier. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 v 
Table of Contents 
Signed statement of sources ........................................................................................ ii 
Abstract ........................................................................................................................iii 
Acknowledgments ....................................................................................................... iv 
Table of contents .......................................................................................................... v 
List of tables................................................................................................................ vii 
List of figures .............................................................................................................. vii 
List of abbreviations .................................................................................................viii 
1. Introduction .............................................................................................................. 1 
1.1 Background .............................................................................................................. 1 
1.2 Treatment guidelines ................................................................................................ 2 
1.3 Adherence: definitions & importance ...................................................................... 6 
1.4 Methods of measuring adherence ............................................................................ 7 
1.5 Forgiveness ............................................................................................................ 10 
1.6 Factors affecting patient adherence to ART .......................................................... 12 
2. Aims ......................................................................................................................... 15 
3. Methodology ........................................................................................................... 16 
3.1 Study design & population..................................................................................... 16 
3.2 Patient selection ..................................................................................................... 17 
3.3 Data collection ....................................................................................................... 18 
3.4 Data analysis .......................................................................................................... 20 
3.5 Ethics...................................................................................................................... 20 
4. Results ..................................................................................................................... 21 
4.1 Demographics ........................................................................................................ 21 
4.2 Patients who changed regimens during study ........................................................ 25 
4.3 Patient adherence rates ........................................................................................... 27 
4.4 Relationship between adherence rates and study variables ................................... 29 
4.5 Drug and regimen characteristics........................................................................... 33 
5. Discussion................................................................................................................ 38 
5.1 Patient Demographics ............................................................................................ 38 
5.2 Adherence rates to ART......................................................................................... 38 
5.3 Factors affecting adherence ................................................................................... 39 
5.4 Forgiveness ............................................................................................................ 41 
 vi 
5.5 Regimen change ..................................................................................................... 41 
5.6 Drug regimens & adherence .................................................................................. 42 
5.7 Study limitations .................................................................................................... 43 
5.8 Applicability to clinical practice ............................................................................ 43 
5.9 Dissemination of findings ...................................................................................... 43 
5.10 Suggestions for future research ............................................................................ 44 
6. Conclusion .............................................................................................................. 45 
7. References ............................................................................................................... 46 
8. Appendices .............................................................................................................. 56 
Appendix 1: FDA approved HIV Medicines ............................................................... 56 
Appendix 2: Data collection form................................................................................ 59 
Appendix 3: Adherence estimation method as reported by Kamowa
29
 ....................... 70 
 
 
 
 
     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 vii 
LIST OF TABLES 
 
Table 1: ASHM What antiretroviral regimen to start guidance document comparing 
recommendations from 4 major international guidelines  ............................................. 5 
Table 2: Nature of data collected for initial study  ...................................................... 18 
Table 3: Personal, social and psychological demographics of study population 
 ..................................................................................................................................... 21 
Table 4: Diagnosis and treatment regimens for non-OI comorbidities ....................... 23 
Table 5: Index and recent CD4 counts and viral load  ................................................. 24 
Table 6: Characteristics of patients who changed ART during study period  ............. 25 
Table 7: Comparison of adherence categories for select characteristics  .................... 29 
Table 8: Relationship between adherence categories (<88%,       and specific 
continuous study variables  .......................................................................................... 31 
Table 9: Adherence rates to specific drugs and formulations  ..................................... 33 
Table 10: Current ART regimen characteristics  ......................................................... 36 
Table 11: Drug combinations adherence distributions  ............................................... 37 
 
 
 
LIST OF FIGURES 
 
Figure 1: Mode of action of various classes of antiretrovirals ...................................... 2 
Figure 2: Overall adherence distribution of the study population  .............................. 27 
Figure 3: Current drug regimen distribution  ............................................................... 36 
 
 
 
 
 
 
 
 
 
 
 viii 
LIST OF ABBREVIATIONS 
 
HIV: Human Immunodeficiency Virus 
AIDS: Acquired Immune Deficiency Syndrome 
CDC: Centre for Disease Control 
FDA: Food and Drug Administration 
cART: combination Antiretroviral Therapy 
ART: Antiretroviral Therapy 
NNRTI: Non-Nucleoside Reverse Transcriptase Inhibitor 
NRTI: Nucleoside Reverse Transcriptase Inhibitor 
PI: Protease Inhibitor 
II: Integrase Inhibitor 
WHO: World Health Organization 
FDC: Fixed Dose Combination 
ASHM: Australasian Society for HIV Medicine 
DHHS: Department of Health and Human Services 
BHIVA: British HIV Association 
EACS: European AIDS Society 
SPSS: Statistical Package for the Social Sciences 
PDC: Proportion of Days covered 
PBS: Pharmaceutical Benefits Scheme 
 
 
 
 1 
1. Introduction 
1.1 Background 
Fewer conditions if indeed any have been more extensively studied in the course of 
human history than the Human Immunodeficiency Virus (HIV), which causes 
Acquired Immune Deficiency Syndrome (AIDS). While some controversy still exists 
to this day on the origin of the virus, and exact details of how it spread to various 
parts of the world. There is no denying the fact that this disease has cost the human 
race several million lives since a routine publication by the Centre for Disease Control 
(CDC) in 1981 highlighted a very rare lung disease (Pneumocystis carinii pneumonia) 
in 5 previously healthy homosexual men
1
. 
 
HIV is a retrovirus that targets the immune system, causing immunodeficiency in 
infected patients. Consequently this leads to a lowering of the body’s ability to fight 
pathogens, thus increasing patient susceptibility to various infections. AIDS is the 
final stage of HIV infection, when the infected patient develops full-blown 
complications of HIV, including a wide variety of opportunistic infections and/ 
cancers. This often happens after 2-15 years of initial infection with the virus. The 
virus is transmitted through the exchange of bodily fluids including blood, breast 
milk, semen and vaginal secretions between infected and non-infected humans. 
Currently the most common modes of transmission include sexual contact (both homo 
and heterosexual), injection drug use, pregnancy & breastfeeding and very rarely 
blood transfusions. 
  
Over 35 million people are currently living with HIV worldwide. In Australia, there 
were over 25,000 people living with diagnosed HIV in 2012
2
. The primary means of 
transmission locally is sexual contact between men
2. While Australia’s HIV 
prevalence rate is relatively low, the number of new HIV diagnoses has gradually 
increased over time
2
. 
 
The drug Zidovudine was the first to be licensed for the treatment of HIV in 1987. 
Since then, the number of drugs licensed by the American Food and Drug 
Administration (FDA) for the management of this condition has increased. There are 
currently 26 agents belonging to 6 different classes, used to manage HIV. These 
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agents act at various points during the lifecycle of the virus to prevent replication and 
consequent proliferation of the virus within the body. 
Figure 1: Diagram showing mode of action of various classes of antiretrovirals 
 
 
Combination Antiretroviral Therapy (cART) formerly known as Highly Active 
Antiretroviral Therapy (HAART) is now standard therapy in the management of HIV. 
Since the concept was introduced in 1996, it is one of the factors credited with the 
increase in life expectancy
3
 seen over the years in infected patients. Current cART 
regimens consist of a combination of at least 3 drugs from two different classes. This 
combination usually contains 2 Nucleoside Transcriptase Inhibitors (NRTI), while the 
third agent can be chosen from any of the remaining 5 groups. Advantages of this 
combination include slowing/halting the development of viral resistance and 
improving patient adherence to treatment by reducing pill burden.  
1.2 Treatment guidelines 
Guidelines on treatment for the disease differ worldwide, with most countries having 
their own local guidelines on various aspects of treatment. These aspects often include 
details such as time of treatment initiation, what first line agents to use and how 
treatment response is to be monitored. Current World Health Organization (WHO) 
treatment guidelines
5
 recommend treatment initiation in treatment naive patients with 
a CD4 count of less than 500 cells/ul. The current 2013 guidelines advocate for earlier 
treatment initiation than the older 2010 guidelines, where treatment initiation was 
pegged at a CD4 cell count of less than 350 cells/ul. This change was as a result of 
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evidence showing that earlier treatment initiation, other than the obvious mortality 
benefit could also prevent the development of several non-AIDS-defining conditions 
including several cardiovascular, kidney and neurocognitive diseases
6, 7
. Earlier 
treatment initiation was also found to reduce HIV transmission rates
8
 and to be useful 
as pre exposure prophylaxis in uninfected individuals
9
. As earlier stated, the current 
treatment standard is the use of cART. The preferred WHO cART regimen is one 
NNRTI + 2 NRTI. The WHO recommended first line regimen consists of a once daily 
Fixed Dose Combination (FDC) of efavirenz+ tenofovir+ lamivudine/emtricitabine.  
 
While the WHO guidelines are quite comprehensive, it can be argued that they are 
more applicable to a public health care perspective that may not be particularly 
applicable locally. Consequently since 2005 in Australia, the United States 
Department for Health and Human Services (DHHS) HIV treatment guidelines have 
been adopted and used as a benchmark to guide clinical decision making in the 
management of HIV. The Australasian society for HIV medicine (ASHM) provides a 
commentary on the DHHS guidelines, especially highlighting technical differences 
(e.g. drug availability &/ formulation) between Australia and the United States. On 
initiation of treatment in treatment naïve patients, the 2013 DHHS guidelines 
recommend the initiation of ARV treatment for all patients infected with HIV
13
. This 
is in contrast to two-major European guideline groups: the British HIV association 
(BHIVA) and the European AIDS Society (EACS). Both of which currently 
recommend treatment initiation at a CD4 cell count of   350 cells/uL, in patients with 
no other complicating conditions
14, 15
. While there is a strong case for early HIV 
treatment initiation, there are also fears in some quarters about the long-term effects 
of this action. Jansson et al
61
 have suggested that currently available medication for 
HIV, even in resource rich settings may be insufficient for life- long treatment 
especially in highly treatment experienced patients or those infected at younger ages. 
 
Several factors have to be considered before choice of an appropriate initial 
antiretroviral regimen can be made. Regimen selection needs to be individualized on 
the basis of toxicity, virologic efficacy, pill burden, dosing frequency, drug-drug 
interaction potential, resistance testing results, and other comorbid conditions
13
. In 
some cases, based on individual patient characteristics and needs, an alternative or 
other regimen may be a preferred regimen for a specific patient. 
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On treatment initiation in treatment naïve individuals, the major guidelines also have 
a wider range of agents to choose from as first line treatments, when compared to the 
WHO guidelines (see table below). In Australia, antiretroviral agents are accessed 
through the highly specialized drug program funded by the commonwealth. Almost 
all of these agents are available under the Pharmaceutical Benefits Scheme (PBS) for 
initial HIV treatment, with the exception of Darunavir and Maraviroc, which are only 
reimbursed if there is prior treatment failure with other antiretroviral regimen(s).  
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Table1: ASHM What antiretroviral regimen to start guidance document 
comparing recommendations from 4 major international guidelines 
 
 
 
 
ASHM- Australasian Society for HIV medicine 
US DHHS- US Department of Health and Human Services 
IAS-USA- International AIDS Society- USA Panel 
BHIVA- British HIV Association 
EACS- European AIDS Clinical Society 
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1.3 Adherence: definitions and importance 
For years, patient compliance or adherence to prescribed medication was believed to 
be the same thing. However recently there has been a move towards separating the 
two concepts, because it is believed that the two terms are far from similar and each 
can have a unique effect on patient outcomes. Compliance has been defined as “the 
extent to which a patients behavior matches the prescribers recommendation”16. This 
term has been largely discontinued in modern medicine because it is believed to be 
“paternalistic” and to imply a lack of patient involvement in own treatment. Mitty and 
Gould
17
 also argue that compliance is an outdated concept suggesting dependence and 
blame, and since it does not improve patient outcomes should be dropped. The WHO 
on the other hand has defined adherence as “the extent to which a person's behavior - 
taking medication, following a diet, and/or executing lifestyle changes, corresponds 
with agreed recommendations from a health care provider”18.This definition is all 
encompassing, and recognizes that adherence can apply to various therapeutic 
behaviors and not just to taking medication.  The International Society for 
Pharmacoeconomics and Outcomes research (ISPOR) adherence definition is more 
medication centered
19
. It includes specifically that the patient agrees to day-to-day 
medication recommendations such as timing, dosage and frequency. ISPOR also lists 
medication persistence as an important component of adherence. Medication 
persistence is the act of continuing to take medication for the recommended duration 
of treatment
19
. This is of paramount importance especially in the management of 
chronic diseases, where patients are often on lifelong medication.  
 
Poor/Non- adherence to prescribed medication has been identified as a worldwide 
public health problem
18
. It is of particular concern to healthcare practitioners, 
systems, and other stakeholders e.g. taxpayers because increasingly, evidence has 
shown that it is highly prevalent, associated with higher healthcare costs and 
contributes to adverse patient outcomes
20
. The WHO estimates that adherence to 
long-term medication by the general populace in developed countries is only around 
50%
18
. But it should be noted that this figure can vary widely depending on various 
factors e.g. the condition/ drug under study and patient demographics. Traditional 
barriers to adherence have been well studied over time, and are known to include 
several factors. These include regimen complexity (number of drugs and dosing 
frequency) and poor patient understanding of the need for adherence. Others can 
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include patient perception of barriers to adherence and the need to modify lifestyles to 
fit treatment regimens
21
. 
 
The primary goal of HIV treatment is to reduce the morbidity and mortality associated 
with the disease. Secondary treatment objectives include suppression of viral 
replication and reducing risk of transmission
13,-15
. To achieve these objectives, the 
importance of both adherence and persistence to ART cannot be overemphasized. 
Evidence has shown that poor ART adherence can be directly linked to failure to 
suppress viral replication and increased development of viral resistance
22-26, 45, 47-49
. 
Other potential problems include development of clinical complications and poor 
survival rates
22-26
. Several studies have clearly demonstrated that real life ART 
adherence rates vary widely, and range from around 50-100%
25, 27-29, 50-52
. These 
estimates differ across the world depending on the method used to measure 
adherence, and the drug under study. 
 
 
1.4 Methods of measuring adherence 
Accurate adherence measurement is essential for effective treatment planning and 
evaluation. Changes in patient outcome need to be able to be linked to the treatment 
regimen. Also several major clinical decisions including regimen/medication change 
need to be made after consideration of reliable adherence rate measurements
18
. While 
there is currently no “gold standard” for adherence measurement30, 32, it can be 
assessed using various methods. Osterberg et al
31
 grouped these methods into direct or 
indirect, other authors prefer the broader terms subjective and objective.  
Direct methods can include directly observed therapy or use of biologic and 
laboratory measurements. Biological measurement utilizes markers that are usually 
blood level measurements of medicine, drug metabolites or other biological 
markers
31
. While these methods are considered to be fairly accurate, they are 
generally not practical for routine clinical use. Plasma drug monitoring cannot be used 
for many drugs, and only reflect recent adherence
32
 (e.g. within the last day). A study 
assessing lopinavir concentrations in 178 ART naïve patients found that up to 66% of 
them, only took the medication correctly in the 3 days preceding their clinic visits
60
. 
Other drawbacks include metabolic variations, either due to diet or other factors, 
which can affect serum levels. And in the case of directly observed therapy, patients 
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have been known to hide pills in their mouths and discard them later
20
. Adherence 
estimation is also possible by monitoring biological changes associated with certain 
medication e.g. increase in mean corpuscular volume associated with zidovudine
32
. 
But it should be noted that this changes are only marginally sensitive and give no 
information on overall adherence patterns. 
 
Indirect methods of adherence assessment include patient questionnaires/self-reports/ 
diaries, healthcare provider adherence estimates, pill counts, rate of prescription 
refills, assessment of the patient’s clinical response, and electronic medication 
monitors
31
. Healthcare provider/ physician adherence estimates especially in HIV 
treatment, have been shown to be inaccurate
33-34
. In one study where physicians and 
nurses were asked to estimate ART adherence in patients, the researchers found that 
the healthcare professionals were wrong at least 30% of the time
33
. 
 
Using Pill counts is another method of adherence estimation. Pill counts involve 
counting the number of pills remaining in the bottle, and are usually carried out by 
healthcare providers or other designated persons
32
. They are tedious, time consuming 
and counting inaccuracies could lead to inaccurate adherence estimations
18, 32
. Other 
potential drawbacks include pill dumping (where patients remove pills from the 
bottles without actually taking them) and other logistic problems. Also patients can 
regard pill counts as threatening or intrusive and pill counts do not capture important 
information like dosage timing and adherence patterns
14, 20, 32
. The MEMS 
(Medication Event Monitoring System) device is a modern update to pill counting. It 
contains a chip that records the time and date every time the medication bottle is 
opened, thus providing better evidence on dosage timing and adherence patterns
18, 32
. 
They are mostly used in clinical trials, as they are too costly for routine use. They are 
subject to some of the same problems as traditional pill counts and the caps can 
malfunction or be manipulated to give inaccurate results.  
 
Adherence estimates from patient self-reports are some of the easiest to obtain, but 
are often wildly inaccurate
18, 20, 32
. They utilize questionnaires, diaries and patient 
recall. The data is subjective and is often biased either by inaccurate patient memory 
or social desirability. In estimation of adherence to ART, it has been shown that all 
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forms of self-report inevitably overestimate adherence when compared to other 
methods
35-37
. 
 
Electronic pharmacy records or pharmacy refill data are now some of the most 
commonly used methods to assess adherence. Obtaining refills and the frequency at 
which refills are acquired reflect both adherence and persistence, both of which are 
required for good chronic disease management. A major advantage of this method is 
elimination of patient recall bias, thus improving reliability. Other benefits include 
allowing retrospective assessment and relative ease of data collection. However, it 
must be noted that that these methods can only measure medication pick up, and work 
on the assumption that the patient actually takes the medication. They give no 
information on dosage timing, and can also only be used when patients access their 
medication from only one source
20
. In addition, they can be difficult to calculate when 
follow –up lengths vary between patients20. Presently two of the most commonly used 
measures of medication adherence using pharmacy data are the medication possession 
ratio (MPR) and proportion of days covered (PDC)
 38-40
. Both of these measures are 
essentially defined as the number of doses dispensed within a specified dispensing 
period
20
.  
The formula for MPR=                                              
                             
While that for PDC= (Total days supply/ total number of days evaluated) * 100. The 
main difference between these 2 measures is that while maximum PDC is 1, 
indicating full adherence, MPR can be greater than 1 because it accounts for 
oversupplies. However PDC is often more commonly used in adherence 
measurements to ART, because it can be used to assess adherence to multiple drugs 
simultaneously over a standardized study period. Several studies have used pharmacy 
refill data to calculate adherence rates to ART
41-43
. A review article by McMahon et 
al
44
 showed the association between adherence rates calculated from pharmacy 
records and several indicators of HIV progression including viral loads, CD4 counts 
and AIDS related mortality. 
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1.5 “Forgiveness” 
Evidence from older trials initially suggested that near perfect adherence levels were 
required in patients on ART. Patterson et al
33
 in their landmark trial on adherence to 
protease inhibitor containing regimens showed that adherence levels of at least 95% 
were required for optimal virological outcomes. This is known as the 95% rule. This 
study and several others that followed after formed the basis of the recommendation 
that adherence levels of       were required in HIV patients 25, 33 46. Adherence of 
at least 95% means that patients only miss one dose a month if on a once daily 
regimen, or less than 3 doses if on a twice daily regimen
29
. At the time un-boosted 
protease inhibitors in combination with 2 nucleoside analogues were widely used in 
clinical practice, unlike the present where most PI containing regimens are boosted by 
addition of ritonavir. Several studies have since shown that current ART regimens 
containing either NNRTI’s or a boosted PI can achieve viral suppression at 
intermediate adherence levels
25, 50-53
. For NNRTI based regimens, these levels have 
been shown to range from 54-90%
25, 50-53
, while that for PI based regimens lies 
between 85-95%
50-51 . “Forgiveness” in terms of ART is used to describe the ability of 
a regimen to achieve or maintain viral suppression in spite of less than recommended 
adherence rates
29, 53
. Forgiveness as a pharmacological parameter cannot be currently 
quantified, but it should be pointed out that this effect is drug specific and depends on 
a variety of factors including host, viral and of course pharmacological.  
 
Pharmacological factors affecting forgiveness include medication half-life and 
antiviral efficacy or potency
53. PI’s like saquinavir, indinavir and nelfinavir that were 
commonly used alone in earlier treatment regimens, have relatively short half-lives. 
This property ensured that their serum concentrations were likely to fall to sub 
inhibitory levels after a missed dose. Ritonavir, a PI commonly used as a booster in 
current PI containing regimens extends the half-life of other PI’s. This ensures that 
adequate serum inhibitory levels are maintained even after a missed dose
54
. It can 
therefore be surmised that drugs with longer elimination half-lives are generally more 
“forgiving” than those with shorter half-lives. However there are exceptions to this 
rule. The prolonged half-life of the NNRTI’s, efavirenz and nevirapine has been 
fingered as a possible cause of development of resistance to these agents
55-56
. Drug 
potency or the efficacy of a pharmacological agent to produce complete viral 
suppression is another characteristic that affects forgiveness. Simply put, patients 
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receiving regimens with low efficacy are more likely to have incomplete viral 
suppression than patients on more potent regimens even at the same level of 
adherence. This finding was highlighted by the trilege study, which showed high 
levels of virologic failure in patients on lamivudine, zidovudine and indinavir 
monotherapy despite good adherence rates and a low resistance mutation rate
53
. This 
finding led the researchers to conclude that the poor forgiveness profile of these 
regimens could be due to their less than ideal pharmacokinetics and antiviral potency. 
 
Host factors equally affect forgiveness. Pharmacokinetic drug parameters including 
absorption, distribution, metabolism and elimination exert varying influences on 
forgiveness by affecting the amount of drug that the virus is exposed to
50
. Examples 
of this phenomenon include impaired absorption of the PI Atazanavir in patients with 
alkaline gastric PH and delayed efavirenz metabolism in patients with a 
polymorphism of a particular subtype of the cytochrome P450 enzyme system
57-58
. 
Recent research also seems to suggest that certain human leukocyte antigens (HLA) 
alleles are related to specific antiretroviral resistance mutations. This means that some 
patients may be genetically predisposed to be resistant to certain agents
59
. This could 
potentially affect the forgiveness of these agents in this particular patient cohort. 
There is also some speculation that the actions of CCR5 antagonists like Maraviroc 
are affected by some patient innate genetic factors
53
. The long-term effects of this on 
the forgiveness of maraviroc remain to be seen.  
 
Finally viral factors can also play a part in determining forgiveness. HIV usually only 
continues to replicate in the presence of antiretroviral medication, if the virus is 
resistant to the agent(s). This is often caused by constant exposure of the virus to sub 
inhibitory drug levels over time. Consequently, at any level of adherence to cART, 
resistance to one or more drugs contained in the regimen is associated with a higher 
chance of virologic failure and thus decreased forgiveness. Development of resistance 
mutations depends on both genotypic and viral factors
53
. And depending on the level 
of resistance conferred by the mutation, adherence levels may or may not affect 
treatment outcomes.  
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1.6 Factors affecting patient adherence to ART 
Several factors have been identified in the literature as affecting patient adherence to 
ART. These factors can be broadly classed into personal characteristics, medication 
characteristics and patient-provider relationship characteristics
67
. Personal 
characteristics include patient beliefs and perceptions on a wide range of issues 
including treatment regimen, ability to cope and the disease itself. Other personal 
factors affecting adherence include demographic and psychosocial factors. Patient 
beliefs on the benefit or lack thereof of their treatment regimen as well as concerns 
over adverse effects have been shown to affect adherence
69
. This effect is not limited 
to individual beliefs alone, and peer group influences as well as social acceptability of 
the regimens need to be taken into account. Patient beliefs on capability are another 
factor potentially affecting ART adherence, and this has given rise to the concept of 
“self efficacy”. Self-efficacy can be described as the individual's own positive 
perception of their ability to carry out a task in a particular situation
67
. In a study of 
adherence to treatment for the opportunistic infection Pneumocystis jiroveci in HIV 
positive patients, Eldred et al concluded that strong self-efficacy was associated with 
high adherence to antiretroviral treatments as well as with prophylactic treatments for 
Pneumocystis jiroveci
68
. Finally patient beliefs about the illness itself can affect 
adherence. Qualitative studies have shown that patients who are afraid of being 
identified as being HIV-positive find it more difficult to follow treatment than those 
who are open about their situation
67
. Another interesting finding is that a prior history 
of opportunistic infections is associated with high adherence behavior with 
antiretroviral treatments. 
 
Demographic and psychosocial factors affecting adherence include age, duration of 
treatment, drug or alcohol problems, social support and psychiatric disorders e.g. 
depression. The role of gender, educational level and ethnicity/race in predicting 
adherence is quite controversial, with some authors arguing for and others against
67, 71, 
73
. One study however noted that female patients were more likely to suffer from 
allergic reactions, gastro-intestinal complications and other non-specific side effects 
from their ART regimen and this may have some bearing on their adherence rates
67
. 
Age has been shown to affect adherence rates in several studies, with younger patients 
seemingly less adherent than their older counterparts
70-71
. A 10-year follow of 1010 
patients in the French APROCO-COPILOTE cohort, which was a study designed to 
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study the disease course of HIV and to document patient experience with HAART 
found that older patients were more likely to be adherent than younger ones
70
. 
Duration on treatment has also been shown to positively affect adherence, with 
patients who have been on treatment for longer periods having better adherence than 
those who have been on treatment for shorter periods of time
70, 72-74
. A study using 
unannounced pill counts to measure ART adherence, found that patients with over 
80% adherence had been on treatment for significantly longer (p=0.0001) than those 
with lower levels
72
. 
Alcohol and drug use (IV and other) also affect the efficacy of cART regimens for 
worse, not only by affecting adherence rates but also by other independent 
mechanisms
67, 70, 75
. These mechanisms can include immunosuppression that worsens 
pre-existing HIV-related immunosuppression, increased hepatotoxicity, and increased 
mortality from non-HIV-related causes e.g. cardiovascular disease
76
. 
Psychiatric disorders have been shown to affect both adherence and persistence to 
ART, thus ultimately affecting disease outcomes 
33, 70, 77
. A systematic review 
containing 82 studies investigating the impact of DSM-IV mental disorders on cART 
adherence found that patients with depression were more likely to have lower cART 
adherence rates. Their findings on other psychological disorders i.e. anxiety, bipolar, 
psychotic and personality disorders were less robust, but also showed some 
association
77
. Social support can also play a role in determining ART adherence
70, 78-
79
. Patients with more social support have better coping behavior and motivation 
levels, leading to higher adherence levels when compared to patients with lower 
support levels. This support can come from partners, close family or other members 
of society.  
 
Increase in medication characteristics such as number of drugs taken daily and 
frequency of dosing; have been shown to affect adherence adversely
67
. The 
type/characteristics of the medication itself can also affect adherence. Research has 
also shows that side effects, and various drug-drug interactions, as well as drug-food 
interactions can be confusing for patients and equally lead to poor adherence. It 
should however be pointed out that most of these issues were problematic in the 
earlier years of cART. Older regimens had onerous pill burdens, complicated dosing 
and problems with toxicity /tolerability
83
. With improvements over the years in HIV 
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medicine, many antiretroviral medications can be taken once daily, without any 
specific dosing requirements and are much less toxic.  
 
Finally, the patient-healthcare provider relationship can have an effect on patient 
adherence. A good relationship characterized by effective communication, has been 
shown in several qualitative studies to be beneficial to patient adherence levels
67
. 
These studies have equally shown that highly adherent patients had smoother 
relationships with their providers, and felt they received better support than less 
adherent ones. The personal character of the health professional as shown in their 
attitude to the client as well as degree of experience with HIV treatment has also been 
shown to affect adherence
67
. 
 
In Australia, several studies have shown certain factors to be predictive of ART non-
adherence locally. Grierson et al
80
 analyzed data collected from a national cross-
sectional survey of 867 patients with HIV, and found several factors associated with 
difficulty taking ART. These included younger age, alcohol and drug use, diagnosis 
of a mental health condition, and living within a regional center. Other predictors 
included taking more than one dose of ART per day, experiencing medication adverse 
events or health service discrimination, certain types of ART regimens and specific 
attitudes towards ART and HIV. McAllister et al
81
 showed that pharmacy dispensing 
and clinic travel costs affected treatment adherence in their patient cohort at the St. 
Vincent’s hospital Sydney. In a study of 80 HIV positive patients at their Melbourne 
clinic, Gibbie et al found that ART non adherence was significantly associated with 
living alone and relationship status
79
. Finally Wilson et al
82
 in their study of 200 
patients attending the Melbourne Sexual Health Centre used patient self report to 
measure adherence. They defined non- adherence as < 98.2%. They found that non-
adherence was strongly associated with using marijuana more than 4 times a week, 
low self-efficacy and having regular daily routines. 
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2. AIMS 
The major aim of this study was to provide additional information into the adherence 
patterns of patients in Australia on anti-retroviral therapy (ART), using prescription 
refill records as the measure of adherence. While earlier studies had assessed 
adherence patterns in the country
28, 79-82
, they used different methods and varying cut 
off points for adherence. Consequently as yet, there is no consensus on adherence 
rates and specific factors affecting ART adherence in Australia. This work aimed to 
shed more light on this situation. Adherence levels were compared with treatment 
outcomes such as CD4 count and viral load. An analysis of patient and drug regimen 
characteristics in relation to adherence patterns was also undertaken. Patient 
adherence to ART is required if positive treatment outcomes both for patients and 
associated public health benefits are to be attained. It is hoped that results of this work 
will be used to optimize adherence patterns, in patients found to have sub-optimal 
adherence. Specifically this work  
1. Compared characteristics of adherent with non-adherent patients (based on 
<88% and  88% cut offs). Comparison variables included demographic data, 
treatment outcomes (CD4 counts & viral load) and other selected information  
2. Tested the hypothesis that forgiveness of currently used ART regimens e.g 
boosted protease inhibitors and efavirenz, should allow treatment outcomes to 
remain constant even in light of sub-optimal adherence. 
3. Explored reasons behind ART regimen change in certain patients, and the 
relationship with their adherence patterns 
4. Determined the influence of drug regimen characteristics (type of formulation 
and drug class) on adherence levels 
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3. METHODOLOGY 
3.1 Study design and population 
This study was a follow up to an initial study carried out by Kamowa
29
 to calculate 
patient ART adherence, and worked with data originally collected for that purpose. 
The original study was a retrospective analysis of adherence to ART medication using 
proportion of days covered (PDC)/ refill adherence as the pharmacy adherence 
measure. Kamowa calculated patient adherence rates using excel spreadsheets and 
SAS software
29
 (see appendix 3 for further detail). Measuring adherence using 
pharmacy records has been validated and extensively used in research into adherence 
patterns to various drug classes including ART.  Several studies have shown an 
association between refill adherence and HIV treatment outcomes including CD4 and 
viral loads
41-44
. The data was collected from the Gold Coast Sexual Health Service, a 
part of Queensland Health providing HIV care. HIV patients attending the clinic filled 
their ART prescriptions at the pharmacy located within the same building. The data 
was collected over a 24-month period beginning in January 2011 to March 2013. The 
24-month period was chosen to allow for adequate observation of the chosen 
variables, as studies of a shorter duration have been shown to be less accurate at 
predicting treatment outcomes
44
. The index date was the first date in 2011 when the 
first prescription was filled. Recent observations were the most current values 
available for each study participant at the end of the study period. The initial study 
classed patients into adherent or non-adherent groups based on whether their PDC 
was   95% or < 95%, as this is the established cut off point for adherence. The 95% 
rule as it is called was initially proposed by Patterson and has been used widely in 
ART adherence studies
33, 46
. This rule suggests that adherence levels of at least 95% 
are required if viral suppression (Viral load < 40 copies/ml) is to be achieved in 
patients taking ART. However, there is some evidence currently that suggests that 
viral suppression can be attained at levels of adherence below 95%. These studies 
have been able to show viral suppression at adherence levels ranging between 54-
90%
25, 50-52
. This study initially proposed to use three cut off points, < 70%, 70-94% 
and  95% to test the hypothesis that viral suppression can still be achieved at levels 
of adherence below the established 95% cut-off. During analysis due to the small size 
of the < 70% adherence group (10 patients), it was decided to divide the study 
population into two groups based on what percentile adherence region they fell into. 
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Patients in the lower 25
th
 percentile had adherence levels of < 88%, and were deemed 
to be less adherent than all the other patients who had adherence levels of   88%.  
 
 
3.2 Patient selection 
All patients that were prescribed ART at the clinic in 2011 were identified. Using 
predefined inclusion and exclusion criteria listed below, patients were either included 
or excluded from the study. 
 
Inclusion criteria 
 Patients aged 18 years or over 
 Patients that had at least 6 months of continuous records and refill data 
 Patients with at least 2 viral load measurements during the study period 
 Patients with at least 2 CD4 cell counts measurements during the study period 
 Patients with index viral loads and CD4 counts results available 
 Patients with at least one viral load and CD4 count result towards the end of 
study. 
Exclusion criteria 
 Patients not taking ART 
 Patients who had been on treatment for less than 6 months or who were lost to 
follow up for at least 6 months during the study period. 
 Patients who had insufficient information to be followed up for at least 24 
months 
 New patients missing at least two viral load measurements or CD4 cell counts 
within the study period 
 Patients missing either an index viral load measurement or CD4 cell count. 
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3.3 Data Collection 
The data analyzed in this study was collected using a specifically designed data 
collection form (See attached in appendix 2). Information on a wide variety of 
variables was collected, as seen in the table below. The data was collected from 
various sources including patient files, pharmacy refill records and Aus  Care 
(Queensland Health Pathology Service System).  
Table 2: Nature of data collected for initial study (taken from Kamowa
29
). 
Category  Selected Parameter  Source  
Regimen  
 
  
 Type of regimen  
Complexity  
 
o  Combination  
o  Pill burden 
o  Frequency of dosing 
o   Food and other 
requirements 
 Changes since started  
 
 
1. Patient file  
2. Pharmacy records 
 
 
 
 
 
 Side effects 
 Reasons for changes 
 Prophylaxis for 
opportunistic 
infections  
 Number of drugs in 
prophylaxis 
prescription  
 
 
 
 
Patient file 
Social and 
psychological  
 
 Substance abuse  
o  History of IV drug 
abuse 
o  Alcohol abuse  
 Depression diagnosis 
 Depressive 
symptoms 
 Smoking status  
 
 
 
Patient file 
Personal   Age  
 Gender  
 Marital status 
 
 
Patient file 
Health status  
 
 Index and Baseline 
CD4 count  
 Index and baseline 
viral load 
1. Patient file 
2. Laboratory test 
results 
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 Duration of diagnosis 
at time of study 
 Duration on ART at 
time of study  
 Co-morbidities 
diagnosed 
 Number of drugs for 
other conditions and 
frequency of dosing 
 
 
Patient file 
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3.4 Data Analysis 
Collected data was then analyzed using the Statistical Package for the Social Sciences 
(SPSS), version 22 and all computations performed using this software. The original 
investigator had previously entered the raw data into SPSS spreadsheets, and 
compiled a codebook for all the variables collected. The new investigator recoded 
several of the collected variables into more relevant categories to create a new 
codebook. Analysis was carried out on all of the collected variables using the 88% 
cut-off, and for some variables, the 95% cut off as well. However, only relevant 
results were reported. Descriptive statistics (means, median and mode) where 
relevant, was obtained using the SPSS program. Categorical data was analyzed using 
either the Chi-square test, or Fishers exact test if any category contained less than 10 
patients. Numerical data were analyzed by means of the independent samples t-test 
and Pearson’s correlations  
 
3.5 Ethics 
As ethical approval granted for the initial study from both Queensland Health (Gold 
Coast Hospital and Health Service) and the School of Pharmacy, University of 
Queensland was still within the 2-year grace period, extensions and/-or amendments 
of the original approvals was sought and granted. The data had already been 
previously de-identified, and only the assigned study number was used in all the 
analyses. The data was securely stored on a password-protected computer throughout 
the study period, and at no point was it ever accessible to any other person other than 
the investigator to prevent any potential privacy violations. 
 
. 
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4. RESULTS 
The data utilized in this work was collected from the Gold Coast Sexual Health 
Service over a 24-month period, spanning January 2011 to March 2013. The average 
study period was 767 days.  From the 278 patients originally screened for the study, 
data was eventually collected from 164 after all the exclusion criteria had been 
utilized.  
4.1 Demographics 
Patient demographic data is summarized in Table 3 
 
 
 
Table 3: Personal, social and psychological demographics of study population 
Characteristic n % Mean (where 
applicable) 
Gender 
Males 
Females 
 
151 
13 
 
92.1 
7.9 
 
Age 
18-30 years 
31-39 years 
40-59 years 
60-79 years 
    years 
 
2 
18 
104 
39 
1 
 
1.2 
11.0 
63.4 
23.8 
0.6 
51 years 
Sexual 
identification 
Homosexual 
(MSM) 
Heterosexual 
 
 
102 
 
62 
 
 
62.2 
 
37.8 
 
History of IDU 
Yes 
No 
Unknown 
 
29 
80 
55 
 
17.7 
48.8 
33.5 
 
Smoking status 
Unknown  
Current smoker 
Never smoked 
Quit  
 
 
41 
73 
39 
11 
 
25 
44.5 
23.8 
6.7 
 
Depression 
diagnosis 
Unknown  
Yes  
No 
 
 
79 
44 
41 
 
 
48.2 
26.8 
25.0 
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Years since HIV 
diagnosis 
Unknown 
6 to < 12 months 
1 to < 2 years 
2 to < 5 years 
   years 
 
 
 
 
19 
5 
6 
12 
122 
 
 
11.6 
3.0 
3.7 
7.3 
74.4 
 
Years on ART 
Unknown 
6 to < 12 months 
1 to < 2 years 
2 to < 5 years 
  5 years 
 
 
22 
8 
17 
15 
102 
 
13.4 
4.9 
10.4 
9.1 
62.2 
 
Total tablet 
burden per day 
1 
2 
3 
4 
    
 
 
 
 
21 
20 
30 
21 
72 
 
 
12.8 
12.2 
18.3 
12.8 
43.9 
4.87  
 
 
It can be seen that over 90% of the study population were male. The majority fell 
within the 40-59-age range, with the mean age of the population being 51 years. Over 
60% of the population identified as homosexual (MSM), and had male partners. 
Twenty-nine (17.7%) had a past history of IDU, out of which only 7 were still 
actively using the study period. Over 40% were smokers. Depression had been 
diagnosed in 44 patients (26.8%), out of which only 24 still had depressive symptoms. 
Most of the study population had been diagnosed with HIV infection for at least 5 
years and had been treated with ART since that time. Data was also collected on 
patient total daily tablet burden. This value consisted of number of tablets for ART; in 
addition to other drugs the patient was on, whether for comorbidities or opportunistic 
infections (OI). Values ranged from 1 to 22, with the average being 4.87tablets/day.  
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The number of patients diagnosed with comorbidities, the number of medicines they 
were on for these conditions and their frequency of dosing can be seen below in Table 
4 
 
Table 4: Diagnosis and treatment regimens for non-OI comorbidities  
 
*OD- once daily, BD- twice daily, TDS- three times a day 
 
70% of patients (115) had at least one non-OI comorbidity diagnosis. All but 2 
patients were on treatment for their comorbidities. The number of medicines 
prescribed for these conditions ranged from 1-21, with the average number of 
medicines being 3.37. Majority (54.8%) were on once daily (OD) treatment regimens 
for their non-OI comorbidities, with the others being on twice a day (BD), three times 
a day (TDS), or other multiple dosing regimens e.g. OD+BD. 
 
 
 
 
 
 
 
Characteristic n % Mean (where 
applicable 
Diagnosis of 
comorbidities 
Unknown 
Yes 
No 
 
 
20 
115 
29 
 
 
12.2 
70.1 
17.7 
 
Prescribed 
medicines 
0 
1 
2 
3 
4 
     
 
 
 
 
2 
33 
19 
19 
4 
15 
 
 
1.9 
31.1 
17.9 
17.9 
7.5 
23.6 
3.37  
Dosing 
frequency 
OD 
BD 
TDS 
Other 
 
 
57 
5 
1 
41 
 
 
54.8 
4.8 
1.0 
39.4 
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The values for CD4 counts and viral loads from the beginning of the study (index 
CD4 count/viral load) and the final values (recent CD4 counts/viral load) at the end of 
the study period are summarized in Table 5 
 
 
 
Table 5: Index and recent CD4 counts and viral load 
Variable n %  
Index CD4 count 
(cells/mm
3
) 
Unknown 
< 200 
     To < 350 
     to      
> 500 
Total 
 
 
 
0 
8 
18 
31 
107 
164 
 
 
0 
4.9 
11.0 
18.9 
65.2 
100 
Mean=612 
Median =570 
Recent CD4 count 
(cells/mm
3
) 
Unknown 
< 200 
     To < 350 
     to      
> 500 
Total 
 
 
4 
4 
16 
33 
107 
164 
 
 
2.4 
2.4 
9.8 
20.1 
65.2 
100 
Mean=652 
Median =620 
Index viral load 
(RNA copies/mL) 
Unknown  
< 40 
    to < 400 
     to < 2000 
       
Total 
 
 
0 
144 
9 
4 
7 
164 
 
 
0 
87.8 
5.5 
2.4 
4.3 
100 
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Recent viral load 
(RNA copies/mL) 
Unknown  
< 40 
    to < 400 
     to < 2000 
       
Total 
 
3 
149 
5 
1 
6 
164 
 
1.8 
90.9 
3.0 
0.6 
3.7 
100 
 
CD4 cell counts at the start of the study averaged 612 cells/mm
3
, and at the end of the 
study period had increased to 652 cells/mm
3
.  Viral loads also mostly followed the 
same pattern, with a slightly higher percentage of patients having undetectable viral 
counts (<40copies/ml) at the end of the study (90.9%) when compared to the 
beginning (87.8%) in spite of 3 patients having unknown viral loads. 
 
4.2 Patients who changed regimens during study 
Information on patients who changed treatment regimens during the study period is 
summarized in Table 6 
 
 
 
 
 
Table 6: Characteristics of patients who changed ART during study period. 
 n % Mean 
Changes to ART during study 
period 
Yes 
No 
 
 
46 
118 
 
 
28.0 
72.0 
 
If yes, No. of times of ART regimen 
change 
1 
2 
3 
 
 
37 
7 
2 
 
 
80.4 
15.2 
4.3 
1.24 
Reason for change 
Intolerable side effects 
Patient request 
Decrease in renal function 
Contraindications 
Side effects and/ Contraindications 
Other 
 
5 
4 
10 
3 
4 
20 
 
10.9 
8.7 
21.7 
6.5 
8.7 
43.5 
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Number of pills/day (old ART 
regimen) 
1 
2 
3 
4 
    
 
 
6 
5 
19 
2 
14 
 
 
13 
10.9 
41.3 
4.3 
30.5 
3.57 
Number of pills/ day (new ART 
regimen) 
1 
2 
3 
4 
    
 
 
 
9 
5 
16 
6 
10 
 
 
19.6 
10.9 
34.8 
13 
21.7 
3.45 
Frequency of dosing-old regimen 
OD 
BD 
OD+ BD 
 
17 
5 
24 
 
37 
10.9 
52.2 
 
Frequency of dosing-new regimen 
OD 
BD 
OD+ BD 
 
18 
5 
23 
 
39.1 
10.9 
50 
 
*OD- once daily, BD- twice daily 
 
Forty six (28%) of patients changed ART regimens during the study period. Majority 
(37) of these patients changed their regimen only once during the study period. The 
most common reason for regimen change was a decrease in renal function. Other 
reasons included intolerable side effects, or other contra-indications. All the other 
patients had various individualized reasons for regimen change, and were classed 
under the other group. The average number of pills daily for both old and newer 
regimens remained mostly constant, as did the dosing frequency. 
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4.3 Patient Adherence rates 
 
Overall patient adherence (PDC) is presented as a bar chart in Figure 2. 
 
Figure. 2: Overall adherence distribution of the study population 
 
 
x-axis: Overall adherence(PDC) 
y-axis: Frequency of patients with particular level of adherence 
 
The measure of adherence used in this study was the proportion of days covered 
(PDC). PDC values range between 0-1. This figure was multiplied by 100 to express 
adherence as a percentage. Overall patient adherence rates ranged from 43% - 100%. 
Mean adherence in the study population was 92%, with a median value of 96%. The 
modal adherence frequency was 100%, with 28 patients (17%) achieving this level of 
adherence.  
The initial proposal was to split adherence into 3 categories, < 70%, 70-94% and   
95%. This was because earlier studies suggested that current drug regimens could 
achieve viral suppression at these levels of adherence. However due to the small size 
of the < 70% group (10 patients), all-subsequent analysis was carried out using 2 
cutoff points of < 88% and   88% because the 88% mark was the cut off point for the 
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lower 25
th
 percentile. This ensured that the sample sizes within the groups would be 
adequate for further analysis. Consequently the < 88% group had 41 patients (25%) 
and all the others were in the   88% group. 
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4.4 Relationship between adherence rates and various study variables 
Selected categorical characteristics of the study population based on the two cut-offs 
(<88% and   88%) are compared in Table 7 below. 
Table 7: Comparison of adherence categories for select characteristics 
Characteristics n             p-value 
Years on ART** 
< 5 years 
  5 years 
Total 
 
40 
102 
142 
 
4(10%) 
31(30.4%) 
35 
 
36(90%) 
71(69.6%) 
107 
0.01
b 
Current regimen 
First –line regimen 
Subsequent/other 
Total 
 
57 
107 
164 
 
18(32.1%) 
23(21.5%) 
41 
 
39(67.9%) 
84(78.5%) 
123 
0.14
a 
Changes to ART 
during study 
period 
Yes 
No 
Total 
 
 
 
46 
118 
164 
 
 
 
10(21.7%) 
31(25.6%) 
41 
 
 
 
36(78.3%) 
87(74.4%) 
123 
0.60
a 
Frequency of 
dosing-old 
OD 
Other (BD or 
OD+ BD) 
Total 
 
 
17 
29 
 
46 
 
 
 
3(17.6%) 
7(24.1%) 
 
10 
 
 
14(82.4%) 
22(75.9%) 
 
36 
0.60
a 
Frequency of 
dosing-current 
OD 
Other (BD/ 
OD+ BD) 
Total 
 
 
102 
62 
 
164 
 
 
28(27.5%) 
13(21.0%) 
 
41 
 
 
74(72.5%) 
49(79.0%) 
 
123 
0.35
a 
Index viral load 
(RNA copies/mL) 
< 40 (undetectable) 
                 
Total 
 
 
144 
20 
164 
 
 
31(21.5%) 
10(50.0%) 
41 
 
 
 
 
113(78.5%) 
10(50.0%) 
123 
0.006
a 
Recent viral load** 
(RNA copies/mL) 
< 40 (undetectable) 
    (Detectable)  
Total 
 
 
 
149 
12 
161 
 
 
32(21.5%) 
8(66.7%) 
40 
 
 
117(78.5%) 
4(33.3%) 
121 
0.002
b 
a-
 using the chi-square test 
b
- using  Fisher’s exact test 
** Test characteristic had missing values, which were excluded from final analysis. 
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Both the chi-square test as well as Fishers exact test was used to test for statistical 
significance. If one of the groups had a cell size of less than 10 patients, Fishers exact 
test was preferred over the chi-square test to allow for a more reliable result. There 
were no statistically significant differences between the groups for most of the 
selected characteristics; these included current regimen, frequency of dosing (for both 
old and new regimens), and changes to ART regimen. P-values for these variables 
ranged from 0.14-0.65. There were however statistically significant associations 
between the adherence groups for duration on ART as well as both index and recent 
viral loads. Duration on ART was significantly associated with adherence level 
(p=0.01, Fisher’s exact test). This result showed that patients who had been on ART 
for    years were significantly more likely to have adherence levels of greater than 
88%, than those who had been on ART for shorter periods of time. Index viral load 
was also statistically associated with adherence level ( 2= 7.593(1), p=0.006), and a 
similar association was seen for viral load at the end of the study period (p=0.002, 
Fisher’s exact test).  As such, patients with undetectable viral loads (either index or 
recent) were significantly more likely to fall in the   88% adherence group, than 
those with detectable viral loads. 
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Several continuous variable characteristics were collected during the course of the study. 
Table 8 summarizes the relationship between these characteristics and the adherence groups. 
These analyses were carried out using the independent samples T-test. 
 
 
 
 
 
Table 8: Relationship between adherence categories (<88%,       and specific 
continuous study variables 
Variable Mean n P-value 
Patient age in years 
<88% 
  88% 
 
49.32 
52.02 
 
41 
123 
0.148 
No of medicines in 
Current ART regimen 
<88% 
  88% 
 
 
2.85 
2.88 
 
 
41 
123 
0.940 
No of medicines in old 
regimen (for those who 
changed regimen during 
study period) 
<88% 
  88% 
 
 
 
 
3.90 
3.47 
 
 
 
 
10 
36 
0.548 
No of tablets prescribed 
for co-morbidities 
<88% 
  88% 
 
 
2.17 
3.70 
 
 
23 
83 
0.004 
Total tablet burden per 
day 
<88% 
  88% 
 
 
4.07 
5.13 
 
 
41 
123 
0.046 
Index CD4 counts 
<88% 
  88% 
 
590 
620 
 
41 
123 
0.545 
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Recent CD4 counts 
<88% 
  88% 
 
613 
664 
 
39 
121 
0.288 
 
There was no significant difference between the average group values for most of the 
variables tested. These variables included both index and recent CD4 cell counts, and number 
of tablets in old and current ART regimens. Average age across adherence categories ranged 
from 49-52, with older patients seemingly having better adherence although this was not 
statistically significant. Statistical significance could be seen in 2 tested variables, which 
included the number of medicines prescribed for co-morbidities and the total tablet burden 
daily. Patients in the     adherence group were on significantly more drugs for their co-
morbidities (mean = 3.7), than patients in the less than 88% adherence group (mean =2.17), 
{t (82.512)= -2.989, p=0.004}. A similar association could be seen between the mean 
numbers of tablets taken daily across the 2 adherence categories. Patients in the  
    adherence group were on the average taking more tablets daily (mean=5.13), than those 
in the < 88% adherence group (mean=4.07), {t (102.775)=-2.024, p=0.04} 
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4.5 Drug and regimen characteristics 
Specific ART medication and the number of study participants prescribed each of these 
medicines during the study period with the average adherence rates to each medicine are 
listed in table 9 
Table 9: Adherence rates to specific drugs and formulations 
Antiretroviral medication n Mean adherence % 
Non-Nucleoside Reverse Transcriptase 
Inhibitors (NNRTI) 
Nevirapine NVP 
Efavirenz EFV 
Etravirine ETR 
 
 
39 
17 
7 
 
 
91.05 
89.88 
95.43 
Nucleoside Reverse Transcriptase Inhibitors 
(NRTI) 
Stavudine d4T 
Zidovudine AZT 
Lamivudine 3TC 
Abacavir ABC 
Didanosine ddI 
Tenofovir TDF 
Kivexa – ABC+3TC 
Trizivir- ABC+3TC+AZT 
Combivir- 3TC+AZT 
Truvada- TDF+ FTC 
 
 
1 
2 
4 
2 
2 
6 
61 
5 
7 
58 
 
 
 
 
 
86.00 
95.50 
87.75 
72.00 
73.50 
94.33 
92.52 
88.80 
93.43 
92.69 
Protease Inhibitors (PI) 
Lopinavir/ritonavir LPV/r 
Atazanavir ATZ 
Darunavir DRV 
Ritonavir RTV 
 
 
16 
33 
8 
35 
 
 
86.88 
87.67 
92.75 
87.74 
Entry Inhibitors 
Enfuvirtide T-20 
Maraviroc MVC 
 
1 
1 
 
100 
100 
Integrase Inhibitors (II) 
Raltegravir RAL 
 
46 
 
91.70 
Combined Agents 
Atripla- TDF+FTC+EFV 
Eviplera- TDF+FTC+RPV 
 
41 
6 
 
94.32 
97.50 
 
This table shows all the drugs the patients enrolled in the study were using during the study 
period and the average adherence rates to them.  It is difficult to draw any definitive 
conclusions due to the wide variation in patient numbers using these agents. However it is 
interesting to note that the average adherence across the drug class protease inhibitors except 
for the drug darunavir, is just under the 88% cut-off used in this study. 
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The drug composition of the various cART regimens the study population was taking is 
shown below in Table 10. They were categorized into first line or other regimens based on 
existing US DHHS guidelines on ART used locally in Australia during the study period i.e. 
January 2011- March 2013.  
  
 
Table 10: Current ART regimen characteristics 
 n % 
Current regimen 
First –line regimen 
Other 
 
56 
108 
 
34.1 
65.9 
First line Regimen 
EFV+ TDF +FTC 
ATZ/r+ TDF+ FTC 
RAL+ TDF+ FTC 
 
 
34 
12 
10 
 
60.7 
21.4 
17.9 
Other regimens 
RAL +ATZ + RTV 
NVP +ABC +3TC 
ABC +3TC + EFV 
ABC + 3TC + 
LPV/r 
NVP + FTC + TDF 
TDF + FTC + RPV 
ABC + 3TC + ATZ 
+ RTV 
RAL + ABC + 3TC 
Others 
 
 
3 
14 
12 
7 
 
13 
5 
4 
 
14 
36 
 
 
2.8 
13 
11.1 
6.5 
 
12 
4.6 
3.7 
 
13 
33.3 
Frequency of 
dosing 
OD 
BD 
OD + BD 
 
 
102 
9 
53 
 
 
62.2 
5.5 
32.3 
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During the study period 34.1% of patients were taking a first-line regimen, while the rest 
were on their second or some other subsequent regimen. All of those on first-line regimens 
were using a backbone combination of 2 NRTI’s containing tenofovir and emtricitabine. 
Majority (60.7%) of these had efavirenz as their third drug, and the others were either on the 
protease inhibitor (PI) combination of atazanavir/ritonavir or the relatively new integrase 
inhibitor raltegravir. Those on their subsequent regimens were mostly on either the abacavir 
+ lamivudine combination or tenofovir + emtricitabine combination as their NRTI backbone. 
Wider third drug combinations were used in this group, including nevirapine, rilpivirine and 
the lopinavir/ritonavir combination. Dosing frequency was mostly once daily (62.2%), but up 
to a third (32.3%) were on dosing regimens that combined both OD and BD dosing. 
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Using a similar format as that used in the Kirby report
2
 for patients enrolled into the 
Australian HIV Observational Database (AHOD), all the current drug regimens the patients 
were on during the study period could be loosely grouped into 5 categories. The proportion of 
the study population in these different categories, at the time of data collection can be seen in 
the following pie chart (Figure 3). The drug combination for each segment is summarised 
below. 
 
 
 
 
 
Segment  Drug combination n 
1 Mono or Double therapy 2 
2 3+: NRTI  PI (not NNRTI’S or II) 
 
31 
3 3+: NRTI  NNRTI (not PI or II) 84 
4 3+: NNRTI + PI,   NRTI’s (not II) 1 
5 3+: II,   NRTI,   NNRTI,   PI 46 
3+- At least 3 drugs, NNRTI- Non Nucleoside Reverse Transcriptase Inhibitors, NRTI- 
Nucleoside Reverse Transcriptase Inhibitors, PI- Protease Inhibitors, II- Integrase Inhibitors 
 
 
Current drug regimen distribution 
Segment 1
Segment 2
Segment 3
Segment 4
Segment 5
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Table 11 shows adherence level distribution of patients using the study cut-offs to the 
regimen categories listed above 
 
Table 11: Drug combinations adherence distributions 
Drug regimen category <88% 
adherence 
  88% adherence Total  
Mono or Double therapy 1(50%) 1(50%) 2 
3+: NRTI  PI (not NNRTI’S 
or II) 
 
14(45.2%) 17(54.8%) 31 
3+: NRTI  NNRTI (not PI or 
II) 
19(22.6%) 65(77.4%) 84 
3+: NNRTI + PI,   NRTI’s 
(not II) 
0(0%) 1(100%) 1 
3+: II,   NRTI,   NNRTI,   
PI 
7(15.2%) 39(84.8%) 46 
 41 123 164 
 
Patient drug regimens as earlier mentioned were grouped into 5 categories. The first category 
consisted of patients using only one or two drugs in their ART regimen. There were only 2 
patients in the study that fell into this category, and they were both using the 
lopinavir/ritonavir combination tablet as their ART regimen. Most current regimens contain 
at least 3 agents as seen in all the subsequent categories. Categories 2 & 3 are based on a 
NRTI backbone (usually consisting of two drugs from this class), and have either a PI or a 
NNRTI as the third agent. Category 4 consists of regimens that include both a NNRTI and a 
PI; a subsequent agent usually a NRTI completes this combination.  The last category 
consists of regimens that contain any drug combination and includes an agent from the 
relatively new ART class Integrase inhibitors. The majority of patients enrolled in the study 
fell into categories 2, 3 and 5. Patients in categories 3 & 5 showed clear distributions into the 
adherence categories, with most patients falling into the   88% group. But once again an 
interesting pattern can be seen in the PI based regimen category (category 2). Patient 
distribution into adherence groups based on the study cut-offs was very similar, unlike the 
other 2 categories where clear differences in adherence rates could be seen. 
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5. Discussion 
This work is a follow up study to an initial exploratory analysis of patient adherence rates to 
ART. It investigates the relationship between various factors and adherence, and compares 
the results with those found in similar studies.  
5.1 Patient demographics 
HIV study populations differ all over the world, depending on geographical region, time of 
data collection and ART regimens used locally. This can often make comparisons between 
study results difficult. The majority of this study population was male (92%), this is similar to 
the gender distribution seen in other studies on ART in Australia
66, 79, 81-82
, since the primary 
means of transmission locally is through sexual contact between men
2
. The average age of 
study participants was 51 years; other ART studies in the Australian setting have shown a 
similar age distribution with average age of participants ranging from 44-52 years
66, 79, 81, 82
. 
This seems to suggest that the local population of HIV positive patients is predominantly 
middle aged. A better part (44%) of patients were also taking at least 5 tablets daily, this is 
also the case seen in some other ART studies locally
66, 82
. There was a high incidence of 
current smoking amongst this patient cohort (44.5%). While this rate is much higher than the 
national Australian prevalence of about 16%
91,
 it is in line with findings from several studies 
that show that smoking in HIV patient populations can be up to three times higher than in the 
general population
92-94
. The rate of depression in this study population was around 15%. 
There is some controversy about actual depression rates in patients with HIV infection, 
though several reviews estimate that the true prevalence of depression in HIV populations 
lies between 1-48%
96-97
. Consequently, this study population is mostly representative of the 
HIV patient population found in Australia, and shared some characteristics with HIV 
populations found in other parts of the world. 
5.2 Adherence rates to ART 
Overall ART adherence in this study ranged from 43-100%, with a mean value of 92%, and a 
median value of 96%. As earlier stated, there is limited information on ART adherence rates 
in Australia. While few studies in Australia have evaluated adherence rates in HIV 
populations, a 2005 study in Melbourne using pharmacy-dispensing records found an average 
adherence rate of 96% in their patient population
28
. Studies from other developed countries 
demonstrate lower adherence rates. Meta analysis of adherence studies in North America in 
2006 found high ART adherence rates (defined as at least 80%) in only 55% of the 
population in the included studies
27
. The same study found that adherence was much better in 
the sub-Saharan African setting, with 77% of patients from the included 27 studies achieving 
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good adherence. These results suggest that ART adherence rates in the Australian setting are 
on the average higher than in other parts of the world.  
 
Several factors could have contributed to the very good adherence rates seen in this study. 
One of these is the quality of care received by the patients attending the clinic. Several 
studies have shown a link between the quality of clinical care received and adherence rates
63-
65, 90
. In a cross sectional analysis of 1743 HIV positive patients, Beach et al found that 
patients who had good relationships with their healthcare providers were significantly more 
likely to have good adherence rates and undetectable viral loads than others
64
. Patient 
engagement with healthcare providers has also been shown to improve quality of life, patient 
self-efficacy and self-esteem
90
. The modal adherence figure in this study was 100%, with 28 
patients (17%) achieving this high adherence level. In a study of experiences and perceptions 
of patients with 100% adherence to ART in a Melbourne clinic, Sidat et al
63
 found that 
maintenance of 100% adherence was mainly related to willingness to live longer & healthier, 
as well as optimal ongoing patient-provider relationships. They also found that improvements 
in clinical condition in addition to disease parameters such as CD4 counts and viral load 
reinforced motivation to continue with a 100% adherence. This knowledge is useful, and can 
help ensure that healthcare professionals work to maintain this adherence level in these 
patients. 
5.3 Factors affecting adherence 
This work mainly used two cutoffs for adherence,   88% and < 88%. If the 88% cutoff 
showed no association for selected variables, the 95% cutoff used in the initial study was 
utilized as well. This was done to further investigate if any association between the study 
variable and adherence at that level could be seen. 
 After excluding patients with unknown smoking status, there was no statistically significant 
difference between the adherence groups using either 88% (p=0.052) or the 95% cut-off point 
used in the initial study (p=0.18) with respect to smoking. In contrast, cigarette smoking has 
been associated with sub-optimal ART adherence rates in several other studies
86-89
. There is 
also some evidence to show that depression/depressive symptoms play a mediating role with 
regards to both smoking and adherence.
88-89
. Webb et al used regression analysis to prove 
their hypothesis that depressive symptoms were related to non-adherence among smokers
89
. 
But possibly due to the low rate of depression in this patient group, no such association could 
be seen. There is currently no evidence that cigarette smoking is directly associated with 
indicators of HIV disease progression e.g. viral loads or CD4 cell counts
87
. However in view 
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of current knowledge about the long-term effects of HIV infection on cardiovascular health 
and the potential risk of myocardial infarctions with the NRTI abacavir
94-95
, cigarette 
smoking may worsen long-term outcomes for some of these patients, and this is a worrisome 
finding. 
 
Age in this patient cohort was also not associated with adherence rates using the 88% cut-off. 
Interestingly though when the 95% cut-off point in the initial study was utilized, a significant 
relationship between age and adherence levels could be seen, with older patients (mean age= 
53) having better adherence than younger patients (mean age=48). Similar results have been 
seen in other studies that show that older age seems to be a predictor for better adherence
70-71
. 
 
Duration on ART was a factor that was predictive of adherence in the study population. 
Patients who had been on ART for 5 years or more were significantly more adherent than 
those who had been on treatment for less than this time. Other studies have found a similar 
effect between treatment duration and adherence rates
70, 72-74
. Several potential explanations 
could be found for this effect, with some authors linking it to increased confidence in the 
drugs effects, establishment of set routines over time and the fact that most drug side effects 
have tapered off or disappeared completely by this time
66
. 
A paradoxical finding of better adherence with increasing number of drugs taken was also 
seen in this study population. Patients in the  88% group were taking significantly more 
drugs for their comorbidities (mean=3.70), than those in the < 88% group (mean= 2.17). A 
similar distribution was seen in the total pill burden daily category. Patients with greater 
adherence were taking on an average 5.13 drugs/day compared to a mean of 4.07 in the lower 
adherence category. While counter intuitive, this effect has equally been reported in other 
studies
66, 86
, and raises questions on traditional beliefs on adherence and tablet burdens. This 
is particularly pertinent because as earlier stated; there was no association between age and 
adherence at the 88% cut-off, which may have proposed a pattern. Older patients are more 
likely to be on more drugs for their co-morbidities, and have higher daily pill burdens than 
younger patients irrespective of HIV status. 
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5.4 Forgiveness 
In this study, measures of disease progression such as CD4 cell counts, and viral loads 
showed interesting relationships with adherence. While there was an increase in mean CD4 
counts during the study period (612 to 652), there was no statistically significant difference in 
CD4 cell counts between the adherence groups (p=0.29). This is not surprising as most major 
HIV guidelines currently recommend using viral load to carry out disease monitoring
5, 13-15
, 
as CD4 counts are subject to biological variations and become largely stable once viral 
suppression has been achieved
10-12
.  
ART forgiveness is used to describe the ability of current ART regimens to maintain viral 
suppression at adherence rates that are lower than recommended
29, 53
. As earlier mentioned 
the original target for adherence was believed to be  95% as proposed by Patterson33.Other 
studies have been able to show viral suppression at adherence levels of 54-90% for ART 
regimens containing either a boosted PI combination or NNRTI
285 50-53
. Kamowa’s earlier 
study using the 95% cutoff found no association between viral suppression and ART 
adherence. This study showed a clear difference in viral suppression between the groups 
using the 88% cutoff. There was a statistically significant difference in viral loads between 
the two adherence groups (p=0.02). More patients with suppressed viral loads (< 40 
copies/ml) were in the  88% adherence group than those with unsuppressed viral loads (> 40 
copies/ml). This clearly supports the forgiveness hypothesis, as the 88% cut off used in this 
study, is lower than the recommended 95% adherence cut-off used in earlier studies. All the 
patients enrolled in the study, were on currently recommended ART regimens, which are 
thought to be more forgiving of poor adherence than earlier regimens. Hence, while these 
results suggest that current regimens may be slightly more forgiving of non-adherence than 
older regimens, adherence rates of at least 88% are required if optimal disease outcomes 
(viral suppression) is to be achieved. 
5.5 Regimen change 
During the period under study, 46 patients (28%) changed their ART drug regimen. The 
majority of these patients did so only once, and the most common reasons cited for the 
changes included either singly or in combination; decreases in renal function, other 
contraindications or adverse effects. Adverse effects were observed in only 21 of these 
patients. While it must be pointed out that these effects were almost uniformly spread out 
across drug classes and regimens, truvada(emtricitabine+tenofovir combination) and 
efavirenz seemed to have a slightly higher association with reported side effects. They each 
had three patients reporting adverse effects. A 2008 study at a primary care clinic at 
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Darlinghurst in Sydney, found that the most common reasons for regimen change included 
tolerability/side effects, virological or immunological failure or poor adherence
62
. This study 
found no difference in the adherence groups between patients who changed their regimen 
during the study period and those who did not (p=0.60). Therefore in this patient group poor 
adherence and virological failure did not play major roles in influencing regimen change. 
5.6 Drug regimens and adherence 
Several factors influence the choice of a suitable ART regimen for patients. These range from 
drug properties e.g. virologic efficacy and pharmacokinetics to individual patient 
characteristics and needs. The ART combinations recorded in this study are in line with 
current DHHS guidelines both for initial and subsequent ART treatment regimens
13
. No 
statistical significance was seen between the adherence groups and regimen type: whether 
initial or subsequent (p=0.14). This study also found no association between frequency of 
dosing and adherence (p=0.35). Frequency of dosing has been long believed to be a factor 
affecting patient adherence to any medication. Surprisingly, other recent research into 
frequency of dosing of ART regimens seems to support this result
84
. A 2014 meta analysis by 
Nachega et al that included 6312 adult HIV patients, concluded that there was only a very 
little difference in adherence between once daily vs. more frequent dosing of ART 
medication. 
 
Because of the wide variety of ART drug combinations used in the clinic, patient ART 
regimens were broadly classed into 5 groups to allow for easier analysis. These groups were 
based on a format used in the 2013 Kirby institute annual surveillance report
2
. The majority 
of the clinic patients were using at least 3 ART drugs, with a NRTI backbone mostly 
containing two drugs. The other agent added to this backbone, was either a NNRTI, PI or II. 
This was remarkably similar to the distribution of ART regimens shown in the Kirby report. 
It was interesting to note that while clear differences could be seen in patient distribution into 
the adherence groups for the NRTI plus NNRTI or II based regimens, with higher numbers of 
patients seen in the  88% group. Patient distribution into the adherence groups for the PI 
based regimen category was almost equal (14vs.17). This would seem to suggest that there is 
a relationship between PI based regimens and adherence. Several studies have suggested that 
PI based regimens are associated with reduced adherence. A retrospective cohort study at the 
university of Alabama found data to suggest that NNRTI-based cART regimens were more 
tolerable to patients, leading to greater durability when compared to both boosted and 
unboosted PI containing regimens
85
. They suggested that better tolerability might be 
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responsible for this effect. The SMART investigators (Strategies for management of 
antiretroviral therapy study) found a similar result
86
. They demonstrated that PI containing 
regimens were associated with sub-optimal adherence. These results however need to be 
interpreted with caution. Several factors affect the choice of patient ART regimen including 
but not limited to previous virologic failure, HIV resistance history and clinician discretion
86
. 
Consequently, this effect could be confounded by several variables including patient 
characteristics and may not be reflective of a true difference. 
5.7 Study limitations 
A major limitation of this study is that it worked with already collected data that was used for 
another study. Consequently if data on a particular aspect was collected in a certain manner, 
it limited the analyses that could be carried out, or in some cases made further analyses 
impossible. For example, while data was collected on alcohol use by the study participants, 
the quantity of alcohol was not predefined. This prevented further analysis of the variable. 
The pill pick up measure (PDC) used to estimate the adherence rates used in this study, 
assumes that the patient takes the medication because they have collected it from the clinic or 
pharmacy. It also assumes that the patient takes the medication at the right dose, at the right 
time and follows any other recommendation related to medication adherence. 
Another limitation that occurred was as a result of the wide variety of ART regimens used by 
the study participants. This made further analysis of regimen characteristics difficult 
 
5.8 Applicability to clinical practice 
The results of this study will be used to optimize patient adherence to ART for patients 
attending the clinic. Patients with sub-optimal adherence can be identified, and specific 
counseling or interventions targeted at improving their adherence rates can be implemented. 
Patients with very high adherence rates will also be encouraged to maintain their adherence 
behavior to maximize outcomes. This study also provides evidence that shows that adherence 
rates of < 88% in patients on current/ newer ART regimens is associated with negative 
outcomes in terms of viral load. This information is relevant to the patients at the clinic and 
other ART patients the world over.  
 
5.9 Dissemination of findings 
The results of this study will be passed on to the clinic to facilitate improvements or 
optimization of patient adherence to ART.  The findings of this study will also be presented 
 44 
at a suitable national or international conference. The two principal researchers also plan to 
work together on a paper that combines both our findings for publication in a suitable journal. 
 
5.10 Suggestions for future research 
It may be worthwhile to investigate further the nature of comorbidities found in the study 
population, and any long-term effects of antiretroviral therapy. With life expectancy in HIV 
positive patients currently predicted to be the same as that of the general population, further 
research will be timely in this area. It may also be useful to investigate the forgiveness of 
newer drug agents such as Integrase Inhibitors, as there is currently a lack of information on 
the forgiveness of these agents 
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6. Conclusion 
This study demonstrated that forgiveness of current antiretroviral regimens consisting of 
agents like boosted PI’s and efavirenz allow for viral suppression to be seen at levels of 
adherence below the recommended standard of 95%. But adherence levels of at least 88% are 
still required if optimal viral suppression is to be achieved. This finding adds to what is 
currently known about the forgiveness of modern ART regimens. In contrast to other studies 
few patient or regimen factors were found which correlated with adherence, with the 
exception of duration on ART, number of pills for comorbidities and total daily pill burden.  
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APPENDIX 1. 
 
FDA Approved HIV Medicines
4 
 
Drug Class Generic Name  
(Other names and 
acronyms) 
Brand Name 
Nucleoside Reverse Transcriptase Inhibitors 
(NRTIs) block reverse transcriptase, an 
enzyme HIV needs to make copies of itself. 
abacavir  
(abacavir sulfate, ABC) 
Ziagen 
didanosine  
(ddI, ddI EC) 
Videx 
Videx EC  
(enteric-coated) 
emtricitabine  
(FTC) 
Emtriva 
lamivudine  
(3TC) 
Epivir 
stavudine  
(d4T) 
Zerit 
tenofovir disoproxil  
fumarate  
(tenofovir DF, TDF)  
Viread 
zidovudine  
(azidothymidine, AZT, 
ZDV) 
Retrovir 
Non Nucleoside Reverse Transcriptase 
Inhibitors (NNRTIs) bind to and later alter 
reverse transcriptase, an enzyme HIV needs to 
make copies of itself. 
delavirdine  
(delavirdine mesylate, 
DLV) 
Rescriptor 
efavirenz  
(EFV) 
Sustiva 
etravirine  
(ETR) 
Intelence 
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Drug Class Generic Name  
(Other names and 
acronyms) 
Brand Name 
nevirapine  
(NVP) 
Viramune 
Viramune XR 
(extended 
release) 
rilpivirine  
(rilpivirine hydrochloride, 
RPV) 
Edurant 
Protease Inhibitors (PIs) block HIV protease, an 
enzyme HIV needs to make copies of itself 
atazanavir  
(atazanavir sulfate, ATV) 
Reyataz 
darunavir  
(darunavir ethanolate, 
DRV) 
Prezista  
fosamprenavir 
(fosamprenavir calcium, 
FPV) 
Lexia 
indinavir  
(indinavir sulfate, IDV) 
Crixivan 
nelfinavir  
(nelfinavir mesylate, NFV) 
Viracept 
ritonavir  
(RTV) 
Norvir 
saquinavir  
(saquinavir mesylate, 
SQV) 
Invirase 
tipranavir  
(TPV) 
Aptivus 
Fusion inhibitors block HIV from entering the 
CD4 cells of the immune system. 
enfuvirtide  
(T-20) 
Fuzeon 
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Drug Class Generic Name  
(Other names and 
acronyms) 
Brand Name 
Entry inhibitors block proteins on the CD4 cells 
that HIV needs to enter the cells. 
maraviroc  
(MVC) 
Selzentry 
Integrase inhibitors block HIV integrase, an 
enzyme HIV needs to make copies of itself. 
dolutegravir  
(DTG)  
Tivicay  
raltegravir  
(RAL) 
Isentress 
Combination HIV medicines contain two or 
more HIV medicines in fixed doses from one or 
more drug classes. 
abacavir and lamivudine  Epzicom 
abacavir, lamivudine, and 
zidovudine 
Trizivir 
efavirenz, emtricitabine, 
and tenofovir DF  
Atripla 
elvitegravir*, cobicistat†, 
emtricitabine, and 
tenofovir DF  
Stribild 
emtricitabine, rilpivirine, 
and tenofovir DF  
Complera 
emtricitabine and tenofovir 
DF  
Truvada 
lamivudine and  
zidovudine 
Combivir 
lopinavir and ritonavir 
(LPV/RTV)  
Kaletra 
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APPENDIX 2 
Data collection form used by Kamowa
29 
PERSONAL INFORMATION               Source: Patient file 
1. Gender 
            Male ☐  Female ☐     Unknown ☐  
 
2. Age (@Jan 2011) 
a. 18-30years ☐ 
b. 31-39years ☐ 
c. 40-59years ☐ 
d. 60-79years ☐ 
e. ≥80years ☐ 
 
3. Marital status 
a. Single ☐ 
b. Married ☐ 
c. Divorced ☐ 
d. Widow  ☐ 
e. Unknown ☐ 
f. Partner ☐ 
 
SOCIAL AND PSYCHOSOCIAL       Source:Patient file  
4. Smoking status 
a. Smoker  ☐ 
b. Never smoked ☐ 
c. Quit ☐ 
d. Unknown  ☐ 
 
5. History of IV drug use        Yes   ☐    No  ☐  Unknown ☐ 
                                         
6. If yes, status of IV drug use  
a. Current IV drug use ☐ 
b. Previous IV drug use ☐ 
 
7. Alcohol use   Yes  ☐     No ☐   Unknown ☐ 
 
 
8. Depression diagnosis  Yes  ☐   No  ☐    Unknown ☐ 
 
9. Depressive symptoms   Yes  ☐ No  ☐     Unknown ☐ 
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HEALTH STATUS       Source: Patient file & AusLab 
10. Number of years since diagnosis of HIV  
a. 6 ≤ 12 months ☐ 
b. 1 – 2 years  ☐ 
c. 2 < 5 years  ☐ 
d. ≥ 5years  ☐ 
e. Unknown ☐ 
 
11. Number of years of  ART  
 
a. 6 ≤ 12 months ☐ 
b. 1 – 2 years  ☐ 
c. 2 < 5 years  ☐ 
d. ≥ 5years  ☐  
e. Unknown ☐ 
 
 
12. Diagnosis of co-morbidities (other than opportunistic infections)      
 Yes   ☐     No   ☐      Unknown ☐ 
 
13. Number of drugs prescribed for co-morbidities  
 
a. One  ☐ 
b. Two  ☐ 
c. Three  ☐ 
d. Four   ☐ 
e. ≥ Five ☐ 
14. Dosing regimen  
 
Frequency  od bd tds qid Other  
 
 
Total number of drugs  
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REGIMEN        
                                                                       Source: Patient file and Pharmacy records  
 
15. Current ART regimen:       1st line  ☐     Subsequent/other ☐ 
 
 
16. First line regimen  
 
a. efavirenz/tenofovir/emtricitabine (Stocrin + Truvada; Atripla)  ☐ 
b. ritonavir-boosted atazanavir + tenofovir/emtricitabine (Norvir + Reyataz + 
Truvada)☐ 
c. raltegravir + tenofovir/emtricitabine (Isentress + Truvada) ☐ 
d. Other ………………………………………………………………… ☐ 
OR 
Subsequent or other regimen  
……………………………………………………………………………………. 
……………………………………………………………………………………. 
……………………………………………………………………………………. 
……………………………………………………………………………………. 
……………………………………………………………………………………. 
……………………………………………………………………………………. 
 
 
17. Changes to ART regimen during study period          Yes  ☐       No ☐ 
 
If yes number of times changes  
a. Once ☐ 
b. Twice ☐ 
c. ≥3 times ☐ 
 
18. If Yes, reasons for change  
a. Intolerable side effects  ☐ 
b. Drug interactions  ☐ 
c. Treatment failure due to non-adherence  ☐ 
d. Treatment failure despite adherence  ☐ 
e. New guideline recommendation  ☐ 
f. New treatment available  ☐  
g. Contraindication ☐ 
h. Other…………………………………………………………….☐ 
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19. Number of tablets per day  
Current regimen 
a. One  ☐ 
b. Two  ☐ 
c. Three ☐ 
d. ≥Four  ☐ 
 
If changed, regimen just prior to change to current   
a. One  ☐ 
b. Two  ☐ 
c. Three ☐ 
d. ≥Four  ☐ 
20. Frequency of dosing  
 
Frequency   Od bd 
 
Total number of 
tablets  
Old regimen 
 (just prior to 
current) 
  
 
Current regimen    
 
 
21. Special considerations for regimen  
  Take with 
meals  
Take at 
bedtime 
(empty 
stomach) 
Together with 
PI  
Number of 
tablets  
Old 
regimen 
(just prior to 
current) 
   
Current 
regimen  
 
 
 
  
 
 
 
22. Current (@end of study) prophylaxis therapy for opportunistic infections    
 Yes  ☐       No  ☐ 
 
23. History of prophylaxis therapy  Yes  ☐       No  ☐ 
 
 
24. Number of drugs for prophylaxis of OI  
a. One  ☐ 
b. Two  ☐ 
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c. Three  ☐ 
d. ≥ Four  ☐ 
 
25. Frequency of dosing  
Frequency  od bd tds qid Other  
 
 
Total number of drugs  
 
     
 
 
26. Total pill burden per day (ART + OI prophylaxis + co-morbidities)  
a. One  ☐ 
b. Two  ☐ 
c. Three  ☐ 
d. Four   ☐ 
e. ≥ Five ☐ 
 
 
 
27. Side effects since started ART      Yes   ☐   No  ☐ 
 
 
28. If yes, offending drug or regimen  
………………………………………………………………………………………………. 
 
 
29. Changes in dose during study period  Yes  ☐       No  ☐ 
 
30. Reason for change  
a. Side effects ☐ 
b. New formulation available ☐ 
c. Decreased pill burden ☐ 
d. Other………………………………………………………… ☐. 
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PRESCRIPTION PICK-UP RECORDS (every 30 days)      
                                                                                                      Source: Pharmacy records  
Rx #  Regimen  Due date  Date filled  # days 
supplied  
#days 
@refill 
Comment  
 
1 
Drug 1☐      
Drug 2☐      
Drug 3☐      
Drug 4☐      
Drug 5 ☐      
 
2 
Drug 1☐      
Drug 2☐      
Drug 3☐      
Drug 4☐      
Drug 5 ☐      
 
3 
Drug 1☐      
Drug 2☐      
Drug 3☐      
Drug 4☐      
Drug 5 ☐      
 
4 
Drug 1☐      
Drug 2☐      
Drug 3☐      
Drug 4☐      
Drug 5 ☐      
 
5 
Drug 1☐      
Drug 2☐      
Drug 3☐      
Drug 4☐      
Drug 5 ☐      
 
6 
Drug 1☐      
Drug 2☐      
Drug 3☐      
Drug 4☐      
Drug 5 ☐      
 
7 
Drug 1☐      
Drug 2☐      
Drug 3☐      
Drug 4☐      
Drug 5 ☐      
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PRESCRIPTION PICK-UP RECORDS (every 30 days)      
                                                                                                      Source: Pharmacy records  
Rx #  Regimen  Due date  Date 
filled  
# days 
supplied  
#days 
@refill 
Comment  
 
8 
Drug 1☐      
Drug 2☐      
Drug 3☐      
Drug 4☐      
Drug 5 ☐      
 
9 
Drug 1☐      
Drug 2☐      
Drug 3☐      
Drug 4☐      
Drug 5 ☐      
 
10 
Drug 1☐      
Drug 2☐      
Drug 3☐      
Drug 4☐      
Drug 5 ☐      
 
11 
Drug 1☐      
Drug 2☐      
Drug 3☐      
Drug 4☐      
Drug 5 ☐      
 
12 
Drug 1☐      
Drug 2☐      
Drug 3☐      
Drug 4☐      
Drug 5 ☐      
 
13 
Drug 1☐      
Drug 2☐      
Drug 3☐      
Drug 4☐      
Drug 5 ☐      
 
14 
Drug 1☐      
Drug 2☐      
Drug 3☐      
Drug 4☐      
Drug 5 ☐      
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PRESCRIPTION PICK-UP RECORDS (every 30 days)      
                                                                                                      Source: Pharmacy records  
Rx 
number  
Regimen  Due 
date  
Date 
filled  
# days 
supplied 
#days 
@refill 
Comment  
 
15 
Drug 1☐      
Drug 2☐      
Drug 3☐      
Drug 4☐      
Drug 5 ☐      
 
16 
Drug 1☐      
Drug 2☐      
Drug 3☐      
Drug 4☐      
Drug 5 ☐      
 
17 
Drug 1☐      
Drug 2☐      
Drug 3☐      
Drug 4☐      
Drug 5 ☐      
 
18 
Drug 1☐      
Drug 2☐      
Drug 3☐      
Drug 4☐      
Drug 5 ☐      
 
19 
Drug 1☐      
Drug 2☐      
Drug 3☐      
Drug 4☐      
Drug 5 ☐      
 
20 
Drug 1☐      
Drug 2☐      
Drug 3☐      
Drug 4☐      
Drug 5 ☐      
 
21 
Drug 1☐      
Drug 2☐      
Drug 3☐      
Drug 4☐      
Drug 5 ☐      
 
22 
Drug 1☐      
Drug 2☐      
Drug 3☐      
Drug 4☐      
Drug 5 ☐      
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PRESCRIPTION PICK-UP RECORDS (every 30 days)      
         Source: Pharmacy records  
 
 
 
 
 
Drug 1 = ………………………………………………………………………………………………..
      
Drug 2 = …………………………………………………………………………………………………..
      
Drug3 = ……………………………………………………………………………………….
  
Drug 4 =…………………………………………………………………………………………………… 
  
Drug 5 =…………………………………………………………………………………………………… 
   
Drug 6 = ……………………………………………………………………………………….. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Rx 
number  
Regimen  Due 
date  
Date 
filled  
# days 
supplied 
#days 
@refill 
Comment  
 
23 
Drug 1☐      
Drug 2☐      
Drug 3☐      
Drug 4☐      
Drug 5 ☐      
 
24 
Drug 1☐      
Drug 2☐      
Drug 3☐      
Drug 4☐      
Drug 5 ☐      
 
25 
Drug 1☐      
Drug 2☐      
Drug 3☐      
Drug 4☐      
Drug 5 ☐      
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TOTAL DAYS SUPPLY AND EPISODE DAYS  
Drug Total # Rx Total days 
supply 
Total tx 
episode days  
# days 
gaps  
Comment  
 
Drug 1 
 
     
 
Drug 2 
 
     
 
Drug 3 
 
 
 
 
    
 
Drug 4 
 
 
 
    
 
Drug 5 
     
 
 
 
Drug 6 
 
     
 
Total days supply for all treatment episodes =  
 
 
 
 
Total treatment episode days = 
 
 
 
LABORATORY VALUES  
 CD4 count Viral load Comments 
 
Baseline  
 
   
@ 6months 
 
   
@ 12months  
 
   
Index date  
 
   
Recent value 1 
 
   
Recent value 2 
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OUTCOMES       Source: Patient file & AusLab 
 
31. Recent (index) CD4 count at start  of study (cells/m2) 
a. <200  ☐ 
b. 200 < 350  ☐ 
c. 350 ≤ 500  ☐ 
d. >500 ☐ 
e.  Unknown  ☐ 
32. Recent  CD4 count-1  at end of study (cells/m2) 
a. <200  ☐ 
b. 200 < 350  ☐ 
c. 350 ≤ 500  ☐ 
d. >500  ☐ 
e. Unknown ☐ 
33. Recent  CD4 count-2  at end of study (cells/m2) 
a. <200  ☐ 
b. 200 < 350  ☐ 
c. 350 ≤ 500  ☐ 
d. >500  ☐ 
e. Unknown ☐ 
34. Recent (index) viral load at start of study (RNA copies/ml)  
a. <40 (undetectable) ☐ 
b. ≥40 < 400 ☐ 
c. ≥400  < 2000 
d. > 2000 ☐ 
e. Unknown ☐ 
35. Viral load-1  at time  near  end study (copies per ml) 
a. <40 (undetectable) ☐ 
b. ≥40 < 400 ☐ 
c. ≥400  < 2000 
d. > 2000 ☐ 
e. Unknown ☐ 
36. Viral load-2  at time  near  end study (copies per ml) 
a. <40 (undetectable) ☐ 
b. ≥40 < 400 ☐ 
c. ≥400  < 2000 
d. > 2000 ☐ 
e. Unknown ☐ 
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Appendix 3 
Adherence estimation as reported by Kamowa29 
The prescription refill history was collected by recording the drugs dispensed, date 
prescription was filled and the number of days supplied deduced from the quantity and dose 
of the drug as shown in Example 1 and Example 2 in Appendix 4 and Appendix 5 
respectively. In a regimen where drug A is taken as: one tablet once a day and drug B is taken 
as: one tablet twice a day, 30 tablets and 60 tablets of drug A and B respectively will be 
dispensed, then days supply will be equal to 30 for both drug A and drug B.  
The due date column on the data collection form was computed during analysis and provided 
a rough picture of the refill adherence in order to identify gaps in-between refills or cases of 
early refill. Although this was not part of the adherence calculation used, it was valuable in 
checking the accuracy of the adherence score and would be valuable in other methods of 
estimating adherence for calculations that incorporate gaps between refills.  
Calculations for estimating adherence were performed for each patient based on the formula 
for proportion of days covered. The PDC is recommended for adherence calculations of 
multiple pill/product regimens and for those which medication cessation and switches are 
more likely as is the case in ART. This is because it has the advantage that it provides 
specific information on medication coverage for each day. For medication switches within 
the therapeutic groups the patient is considered to be compliant if the prescriptions for the 
new therapy are filled. The PDC was a value between 0 and 1 and was multiplied by 100 to 
obtain the adherence value as a percentage. If a patient had an oversupply, the PDC was 
truncated to 1. In the ART regimens comprising multiple pills/products, the mean of each 
patient’s PDC was used to obtain an overall adherence value. The period of study for patients 
was calculated from their index date and end of study date   
The compliance estimations were calculated using Excel, Statistical Package for Social 
Science (SPSS) and Statistical Analysis Software (SAS). The refill history spread sheet data 
for each patient was re-arranged into the variables of: member_id, drug, fill (fill date) days 
(number of days_supply) for analysis in SAS using the SAS code for adherence calculations 
developed by Scott et al . 
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